초록 ▼

The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the o

The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor .beta.1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor .beta.1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffinose, sucrose, mannitol, etc.), medium (such as agents with intermediate molecular weights of around 600-2,000) and high (such as hydroxyethyl starch) molecular weight agents osmotic buffering agents. The invention is also directed to new post-transplantation treatments such as the use of transforming growth factor .beta.1, N-acetylcysteine and aurothioglucose.

대표청구항 ▼

[ What is claimed is:] [1.] A method for preparing an organ for transplantation after its cryopreservation with a cryoprotectant, comprising:(a) warming said organ to a temperature which permits reperfusion of said organ, wherein damage to said organ is minimized;(b) perfusing said organ with a comp

[ What is claimed is:] [1.] A method for preparing an organ for transplantation after its cryopreservation with a cryoprotectant, comprising:(a) warming said organ to a temperature which permits reperfusion of said organ, wherein damage to said organ is minimized;(b) perfusing said organ with a composition comprising a cryoprotectant and at least two osmotic buffering agents, wherein said composition has a non-vitrifiable concentration of cryoprotectant that is less than the concentration of cryoprotectant used for said cryopreservation, and wherein said at least two osmotic buffering agents includes at least one low molecular weight osmotic buffering agent having a molecular weight of less than 1000 daltons and at least one high molecular weight osmotic buffering agent having a molecular weight of at least 1000 daltons; and(c) perfusing substantially all of said cryoprotectant out of said organ while concurrently increasing the temperature of said organ to render said organ suitable for transplantation.